BRAF inhibition in melanoma is associated with the dysregulation of histone methylation and histone methyltransferases

The development of mutant BRAF inhibitors has improved the outcome for melanoma patients with BRAFV600E mutations. Although the initial response to these inhibitors can be dramatic, sometimes resulting in complete tumor regression, the majority of melanomas become resistant. To study resistance to B...

Full description

Bibliographic Details
Main Authors: Florina Grigore, Hana Yang, Nicholas D. Hanson, Matthew W. VanBrocklin, Aaron L. Sarver, James P. Robinson
Format: Article
Language:English
Published: Elsevier 2020-09-01
Series:Neoplasia: An International Journal for Oncology Research
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S1476558620301287